Member Info for Bebeto

By my own reckoning, six more sessions before results, 7am next Thursday 16th July is marked in my diary.

Shareprice has to rise 47% to get back into mid-fifties but only 23.5% rise to 46.3p. Maths can be your friend.

The results are coming from these locations;

Locations
United Kingdom
Belfast City Hospital Not yet recruiting
Belfast, United Kingdom, BT9 7AB
Contact: Lorcan McGarvey, MD FRCP
Queen Elizabeth Hospital, Recruiting
Birmingham, United Kingdom, B15 2GW
Contact: Davinder Dosanjh, DPhil, MRCP, FHEA
Bradford Royal Infirmary Recruiting
Bradford, United Kingdom, BD9 6RJ
Contact: Dinesh Saralaya, MBBS MD MRCP FRCP
Hull and East Yorkshire NHS Trust, Castle Hill Hospital, Recruiting
Hull, United Kingdom, HU16 5JQ
Contact: Michael Crooks, MBBS
Glenfield Hospital, Recruiting
Leicester, United Kingdom, LE3 9QP
Contact: Salman Siddiqui, Fellow of the Royal College of
Wythenshawe Hospital Recruiting
Manchester, United Kingdom, M23 9LT
Contact: Jaclyn Smith, MB ChB MRCP PhD FRCP
City Campus of Nottingham University Recruiting
Nottingham, United Kingdom, NG5 1PB
Contact: Tim Harrison, MBBS FRCP MD
John Radcliffe Hospital Recruiting
Oxford, United Kingdom, OX3 9DU
Contact: Najib Rahman, MB BCh MA
University Hospital Southampton Nhs Foundation Trust Recruiting
Southampton, United Kingdom, SO16 6YD
Contact: Tom Wilkinson t.wilkinson@soton.ac.uk
Principal Investigator: Tom Wilkinson

The results will be the same as the astrazeneca trial: AZD9412 is SNG 001
"Treatment with AZD9412 switched on antiviral responses in the lungs, improved morning peak flow (a measure of lung function), and was well tolerated

· The study however, did not meet AstraZeneca's predefined criteria for progression, and they have elected to return the rights to AZD9412 to Synairgen.. Treatment with inhaled interferon beta did however switch on the lungs' antiviral defences (as measured by blood levels of the antiviral biomarker CXCL10), have a beneficial effect on lung function (Morning Peak Expiratory Flow: difference of 19.7 litres per minute average over the first 7 days of treatment (p=0.01)), and was well tolerated. Effects on biomarkers, lung function and the good tolerability profile "

Yes I don't use this either, just noticed when cross referencing.
I'm going to say our results will be the same as this;
"Treatment with inhaled interferon beta did however switch on the lungs' antiviral defences (as measured by blood levels of the antiviral biomarker CXCL10), have a beneficial effect on lung function (Morning Peak Expiratory Flow: difference of 19.7 litres per minute average over the first 7 days of treatment (p=0.01)), and was well tolerated. Effects on biomarkers, lung function and the good tolerability profile were consistent with the Company's own Phase II trial (SG005). "

Ok well I wonder why the RNS is NOT on this website.?

Wonder why this RNS has been removed? Astrazeneca cancelled their P2 trial but it left positive data for us. Expecting positive results coming here now.

https://markets.ft.com/data/announce/full?dockey=1323-13206094-0G2UV3F6787OLFH4CT3HTRNKEJ

Synairgen PLC
AZD9412 Update
April 27, 2017Source: RNS
RNS Number : 4767D
Synairgen plc
27 April 2017


Press release

Synairgen plc

('Synairgen' or the 'Company')

AZD9412 Update



· Cold infections did not affect trial patients' asthma in the INEXAS study as much as predicted, meaning that the drug's effects on severe exacerbations could not be determined

· Treatment with AZD9412 switched on antiviral responses in the lungs, improved morning peak flow (a measure of lung function), and was well tolerated

· The study however, did not meet AstraZeneca's predefined criteria for progression, and they have elected to return the rights to AZD9412 to Synairgen

· Synairgen will conduct further analysis of the data and determine future development routes



Southampton, UK - 27th April 2017: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today provides an update on AZD9412 (inhaled interferon beta).

In October 2016 Synairgen provided the market with an update on the INEXAS trial of AZD9412, a novel, inhaled interferon beta that supports the immune system by correcting a deficiency which makes patients vulnerable to respiratory tract viral infections (primarily common cold viruses). The trial was stopped early due to a low severe exacerbation event rate which compromised an assessment of this endpoint (number of severe exacerbations).

Treatment with inhaled interferon beta did however switch on the lungs' antiviral defences (as measured by blood levels of the antiviral biomarker CXCL10), have a beneficial effect on lung function (Morning Peak Expiratory Flow: difference of 19.7 litres per minute average over the first 7 days of treatment (p=0.01)), and was well tolerated. Effects on biomarkers, lung function and the good tolerability profile were consistent with the Company's own Phase II trial (SG005).

The study did not however meet AstraZeneca's predefined criteria for progression, and they have elected to return the rights to AZD9412 to Synairgen.

Further analysis of samples from the trial is being completed by AstraZeneca. Data from this sample analysis and the clinical trial data will be licensed to Synairgen. Synairgen will complete the data analysis and will use this as a basis to determine the future direction of the programme.

Professor Stephen Holgate CBE, Medical Research Council Clinical Professor of Immunopharmacology at the University of Southampton, said: "We believe that the biomarker, lung function and safety data from this and our previous study continue to support the potential of inhaled interferon beta as a treatment for vulnerable patients whose disease control is badly affected when they get a cold. We are particularly interested in the potential for COPD, where exacerbations are associated with disease progression and an increased risk of dying. Since we licensed this programme to AstraZeneca, the weight of data linking viruses

I know all these shareprice shenanigans has nothing to do with the trial but because of them, I really fancy the results to be positive. !

Another session closer to finding out

Got quoted 38.49 to buy, some buys must have been printed as sells again.

Antiquated system showing buys as sells.

The dataset results will be in a ordinal scale because ordinal analysis of outcome substantially increases statistical power.

There's always another share, but once the world can effectively treat Covid-19 the need for testing will become virtually obsolete. SNG001 could well become part of the solution, if it does then the rewards could be endless and if it doesn't then the shareprice will half, I'm prepared to take that risk and looking forward to seeing the results.

Positive news regarding Jamaica farm down - licence extension and we'll surpass 6p for sure, as it has massive potential 229Mb

Wait for the drilling to stop and they start reckoning up the MRE. Every man and his dingo will be taking up positions here. IMO

Agree, Acacia have no bearing on the results or have any information regarding the results, they have their own agenda.

$20 a barrel is break even and we're constantly over that threshold. The shareprice can do it's thing clearing the overhang and the balance sheet can do it's thing expanding the coffers.

Agree, happy to hold here and slowly increase holding at these levels (under the 3p placing is absolute bargain) in the meantime the company is generating a profit.

If the results are very good and especially the at home part of the trial, then SNG001 will have worldwide exposure and I don't see how you could put a percentage on that at this time.

Agree yes, they have left the door open for the COPD interim analysis results to support either, and, or the SNG001 hospital & at home trials. This is the reason the timeline is left open as "summer".